Abstract:Objective: Nuclear receptor Peroxisome Proliferator-Activated Receptor γ (PPARγ) is a promising target for the treatment of type 2 diabetes. The antidiabetic drug thiazolidinediones (TZDs) are potent insulin sensitizers as full agonists of PPARγ, but cause unwanted side effects. Recent discoveries have shown that TZDs improve insulin sensitivity by blocking PPARγ phosphorylation at S273, which decouples the full agonism-associated side effects. PPARγ ligands that act through the blockage of PPARγ phosphorylation but lack the full agonist activity would be expected to improve insulin sensitivity without TZD-associated side effects, however, chemicals that carry such traits and bind to PPARγ with high-affinity are lacking. Moreover, TZDs are known to promote white-to-brown adipocyte conversion and energy expenditure and appear to require their full agonism on PPARγ for this activity. It is unknown whether a partial or non-TZD agonist of PPARγ is capable of promoting browning effect. In this study, we developed a novel non-TZD partial agonist of PPARγ and investigated its function on insulin sensitivity and white-to-brown conversion and energy expenditure in diet-induced obese mice. Methods: A novel indole-based chemical WO95E was designed via medicinal chemistry and tested for PPARγ binding and activity and for the effect on PPARγ phosphorylation. Diet-induced obese mice were administered with WO95E for 4 weeks. Insulin sensitivity, glucose tolerance, body weight, fat tissue weight, adipocyte size, morphology, energy expenditure, and expression levels of genes involved in PPARγ activity, thermogenesis/browning, and TZD-related side effects were evaluated. Results: WO95E binds to PPARγ with high affinity and acts as a PPARγ partial agonist. WO95E inhibits PPARγ phosphorylation and regulates PPARγ phosphorylation-dependent genes. WO95E ameliorates insulin resistance and glucose tolerance in mice of diet-induced obesity, with minimal TZD use-associated side effects. We found that WO95E promotes white-to-brown adipocyte conversion and energy expenditure and hence protects against diet-induced obesity. WO95E decreases the size of adipocytes and suppresses adipose tissue inflammation. WO95E also suppresses obesity-associated liver steatosis. Conclusions: WO95E improves insulin sensitivity and glucose homeostasis and promotes browning and energy expenditure by acting as a novel PPARγ phosphorylation inhibitor/partial agonist. Our findings suggest the potential of this compound or its derivative for the therapeutic treatment of insulin resistance and obesity.

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptorγwith Excellent Effect on Insulin Resistance and Type 2 Diabetes

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

P633H, a novel dual agonist at peroxisome proliferator-activated receptors α and γ, with different anti-diabetic effects in db/db and KK-A y mice

CMHX008, a Novel Peroxisome Proliferator-Activated Receptor Γ Partial Agonist, Enhances Insulin Sensitivity in Vitro and in Vivo.

A Novel Dual Peroxisome Proliferator-Activated Receptors Α and Γ Agonist with Beneficial Effects on Insulin Resistance and Lipid Metabolism

C333H,a Novel PPARα/γ Dual Agonist,has Beneficial Effects on Insulin Resistance and Lipid Metabolism

A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice

Identification of Novel PPARα/γ Dual Agonists by Virtual Screening, ADMET Prediction and Molecular Dynamics Simulations.

Identification of a Novel Selective Agonist of PPARγ with No Promotion of Adipogenesis and Less Inhibition of Osteoblastogenesis

Progress in agonists and antagonists of peroxisome proliferator-activated receptor γ

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes

Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ

Discovery of First-in-class Thiazole-Based Dual FFA1/PPARδ Agonists As Potential Anti-Diabetic Agents

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones As Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents

Identification of Novel PPARα/γ Dual Agonists by Pharmacophore Screening, Docking Analysis, ADMET Prediction and Molecular Dynamics Simulations.

Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation

A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.

Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation